PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases


Cite item

Full Text

Abstract

Aim. We study the dynamics of oxidatively modified low-density lipoprotein (ox-LDL) content in blood plasma, as well as changes in the activity of key antioxidant enzymes such as Se-containing glutathione peroxidase (GSH-Px) Cu,Zn-superoxide dismutase (SOD) and catalase in erythrocytes of patients with coronary artery disease during treatment with PCSK9 inhibitor (ewolocumab). Materials and methods. The study included 9 men (59 ± 10 years) with coronary artery disease with atherosclerotic lesion at least one main coronary artery according to coronary angiography. Patients took standard therapy before taking the study, everyone took the maximum tolerated dose of statins. Since the target cholesterol levels of low-density lipoprotein cholesterol (LDL-C) were not achieved during the statin therapy, patients were prescribed lipid-lowering therapy with the inclusion of the inhibitor PCSK9-emocoucumab from Amgen 420 mg once a month. The content of lipid metabolism indices was determined by standard biochemical methods. The level of ox-LDL in the blood plasma was determined by the immunochemical method. The activity of antioxidant enzymes was determined in blood erythrocytes using biochemical techniques Results. Cholesterol-lowering drug of the new type - inhibitor protein convertase subtilisin/kexin type 9 (PCSK9) evolocumab (Amgen) not only effectively lowers the level of cholesterol in low density lipoprotein (LDL), but also significantly reduces the content of oxdatively modified LDL in blood plasma. Unlike statins, the inhibitor of PCSK9 does not cause a decrease in the activity of antioxidant enzymes of the blood. Conclusion. PCSK9 inhibitor has no effect on the parameters of oxidative stress.

About the authors

V Z Lankin

FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation

Email: lankin941@mail.ru
д.б.н., проф., руководитель отд. биохимии свободнорадикальных процессов Moscow, Russia

A K Tikhaze

FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation

Email: allatikhaze@yandex.ru
д.м.н., проф., в.н.с. отд. биохимии свободнорадикальных процессов Moscow, Russia

M Viigimaa

Center for Cardiology of Tallinn University of Technology

Email: MargusViigimaa@regionaalhaigla.ee
д.м.н., проф., руководитель центра кардиологии Tallinn, Estonia

I E Chazova

FSBI "National Medical Research Cardiology Center" of the Ministry of Health of the Russian Federation

Email: c34h@yandex.ru
д.м.н., проф., акад. РАН, директор Института клинической кардиологии им. А.Л. Мясникова Moscow, Russia

References

  1. Nawarskas J.J. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13(2):76-9. https://doi.org/10.1097/01.crd. 0000154790. 42283.a1
  2. Lankin V.Z, Tikhaze A.K, Kukharchuk V.V, Konovalova G.G, Pisarenko O.I, Kaminnyi A.I, Shumaev K.B, Belenkov Y.N. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol Cell Biochem. 2003;249(1-2):129-40.
  3. Lankin V.Z, Tikhaze A.K. Free radical lipoperoxidation during atherosclerosis and antioxidative therapy of this disease. In: Tomasi A., et al., eds. Free Radicals, Nitric Oxide and Inflammation: Molecular, Biochemical and Clinical Aspects. Amsterdam, etc.: IOS Press, NATO Science Series. 2003;344:218-31.
  4. Moosmann B, Behl C. Selenoprotein synthesis and side - effects of statins. Lancet. 2004;363(9412):892-4. https://doi.org/10.1016/S0140-6736(04)15739-5
  5. Littlefield N, Beckstrand R.L, Luthy K.E. Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation. J Am Assoc Nurse Pract. 2014;26(2):85-90. https://doi.10.1002/2327-6924.12046
  6. Pisarenko O.I, Studneva I.M, Lankin V.Z, Konovalova G.G, Tikhaze A.K, Kaminnaya V.I, Belenkov Y.N. Inhibitor of beta - hydroxyl - beta - methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats. Bull Exp Biol Med. 2001;132(4):956-8.
  7. Steinberg D, Witztum J.L. Oxidized low - density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(12):2311-6. https://doi.org/10.1161/ATVBAHA.108.179697
  8. Lankin V.Z, Tikhaze A.K. Role of Oxidative Stress in the Genesis of Atherosclerosis and Diabetes Mellitus: A Personal Look Back on 50 Years of Research. Сurr Аging Sci. 2017;10(1):18-25. https://doi.org/10.2174/ 1874609809666160926142640
  9. Lankin V.Z, Tikhaze A.K, Konovalova G.G, Kumskova E.M, Shumaev K.B. Aldehyde - dependent modification of low density lipoproteins. In: Handbook of Lipoprotein Research. NY. Nova Sci. 2010:85-107.
  10. Pedersen T.R. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10 (Suppl 1):10-7. https://doi.org/10.2165/1158822-S0-000000000-00000
  11. Koren M.J, Lundqvist P, Bolognese M, Neutel J.M, Monsalvo M.L, Yang J, Kim J.B, Scott R, Wasserman S.M, Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23): 2531-40. https://doi.org/10.1016/j.jacc.2014.03.018
  12. Koren M.J, Sabatine M.S, Giugliano R.P, Langslet G, Wiviott S.D, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal F.J. Long - term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years from the Open-Label OSLER-1 Extension Study. JAMA Сardiol. 2017;2(6):598-607. https://doi.org/10.1001/jamacardio.2017. 0747
  13. Viigimaa M, Abina J, Zemtsovskaya G, Tikhaze A, Konovalova G, Kumskova E, Lankin V. Malondialdehyde - modified low - density lipoproteins as biomarker for atherosclerosis. Blood Press. 2010;19(3):164-8. https://doi.org/10.3109/08037051.2010.484158
  14. Lankin V.Z, Konovalova G.G, Tikhaze A.K, Shumaev K.B, Belova-Kumskova E.M, Grechnikova M.A, Viigimaa M. Aldehyde inhibition of antioxidant enzymes in blood of diabetic patients. J Diabetes. 2016;8(3):398-404. https://doi.org/10.1111/1753-0407.12309
  15. Chrysant S.G. New onset diabetes mellitus induced by statins: current evidence. Postgrad Med. 2017;129(4):430-5. https://doi.org/10.1080/ 00325481.2017.1292107

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies